Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers Meeting Abstract
| Authors: | Yap, T. A.; Krebs, M. G.; Postel-Vinay, S.; Bang, Y. J.; El-Khoueiry, A.; Abida, W.; Harrington, K.; Sundar, R.; Carter, L.; Castanon-Alvarez, E.; Im, S. A.; Berges, A.; Khan, M.; Stephens, C.; Ross, G.; Soria, J. C. |
| Abstract Title: | Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers |
| Meeting Title: | 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics |
| Journal Title: | European Journal of Cancer |
| Volume: | 69 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2016 Nov 29-Dec 2 |
| Meeting Location: | Munich, Germany |
| ISSN: | 0959-8049 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2016-12-01 |
| Start Page: | S2 |
| Language: | English |
| ACCESSION: | WOS:000390503500002 |
| PROVIDER: | wos |
| DOI: | 10.1016/S0959-8049(16)32607-7 |
| Notes: | Meeting Abstract: 1LBA -- 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics -- NOV 29-DEC 02, 2016 -- Munich, GERMANY -- Source: Wos |
